{"nctId":"NCT01138501","briefTitle":"Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A","startDateStruct":{"date":"2010-06"},"conditions":["Congenital Bleeding Disorder","Haemophilia A"],"count":65,"armGroups":[{"label":"rFVIII","type":"EXPERIMENTAL","interventionNames":["Drug: turoctocog alfa"]}],"interventions":[{"name":"turoctocog alfa","otherNames":[]},{"name":"turoctocog alfa","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male patients with severe (baseline FVIII less than or equal to 1%) haemophilia A\n* Age below 12 years and weight at least 11 kg\n\nExclusion Criteria:\n\n* Surgery planned to occur during trial participation (exceptions are port placement, dental extractions, and minor, uncomplicated emergent procedures)\n* Congenital or acquired coagulation disorders other than haemophilia A\n* Any history of FVIII inhibitors (greater than or equal to 0.6 BU/mL)","healthyVolunteers":false,"sex":"MALE","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Incidence Rate of FVIII Inhibitors (Greater Than or Equal to 0.6 Bethesda Units (BU))","description":"The incidence rate of FVIII inhibitors was calculated by including all patients with inhibitors in the nominator and including all patients with a minimum 50 exposure plus any patients with less than 50 exposures but with inhibitors in denominator.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Adverse Events (AEs)","description":"Adverse event was defined as events occurring after administration of trial product. Severe AEs: considerable interference with subject's daily activities, unacceptable. Moderate AEs: Marked symptoms, moderate interference with the patient's daily activities. Mild AEs: No or transient symptoms, no interference with the patient's daily activities. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":63},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Vomiting","Contusion","Headache"]}}}